Faster Hypernatremia Correction & Long-Acting Antibiotics for Staph Bacteremia (w/ Dr. Kevin Baker)

Episode 4: Faster Hypernatremia Correction & Long-Acting Antibiotics for Staph BacteremiaWith Special Guest Dr. Kevin BakerIn this episode of Inpatient Update, Dr. Mason Turner is joined by hospitalist Dr. Kevin Baker to discuss two studies that challenge long-held dogma in inpatient medicine:Faster correction of hypernatremia — is the traditional “go slow” rule actually harming patients?Dalbavancin for Staph aureus bacteremia (DOTS Trial) — can two long-acting antibiotic injections replace weeks of IV therapy and PICC lines?Practical take-homes, real-world discussion, and what to change on rounds tomorrow (with a couple of bourbons).Articles & PubMed LinksClinical outcomes of early fast compared to slow sodium correction rate in adults with severe hypernatremia: A comparative effectiveness studyJournal of Critical Care (2025)Key FindingsFaster correction associated with lower 30-day mortalityShorter ICU length of stayShorter hospital length of stayNo signal for neurologic complications from rapid correctionSupporting data from prior studies:2023 JAMA observational cohort Faster correction associated with lower mortality No neurologic complications reported2025 Journal of Critical Care meta-analysis Faster correction not associated with worse outcomesTakeawayFor adult hypernatremia, especially in critically ill patients, more aggressive correction appears safe and may improve outcomes.Pubmed: https://pubmed.ncbi.nlm.nih.gov/41240509/Dalbavancin for Treatment of Staphylococcus aureus Bacteremia: The DOTS Randomized Clinical TrialJAMA 2025Compared:Standard Therapy4–8 weeks IV antibioticsCefazolin / anti-staphylococcal penicillin (MSSA)Vancomycin or daptomycin (MRSA)vsDalbavancin Strategy1500 mg IV day 11500 mg IV day 8Long-acting lipoglycopeptide with ~14-day half-life, allowing completion of therapy without PICC lines.PopulationComplicated Staph aureus bacteremiaKey ResultsClinical efficacy:Dalbavancin: 73%Standard therapy: 72%Microbiologic success:Dalbavancin: 98.8%Standard therapy: 96.3%Met criteria for non-inferiority.TakeawayFor selected patients with cleared Staph aureus bacteremia, two doses of dalbavancin may replace weeks of IV antibiotics and PICC lines.Potential advantages:Avoids central line complicationsSimplifies discharge planningUseful in patients with difficult social situations or IV access concernsPubmed: https://pubmed.ncbi.nlm.nih.gov/40802264/Practice-Changing TakeawaysHypernatremia: Faster correction appears safe in adults and IMPROVES mortality.Staph bacteremia: Long-acting dalbavancin offers a PICC-free alternative for completing therapy in selected patients.Hospital medicine continues to move toward shorter and simpler antibiotic strategies.Support the showWant the cited articles and key takeaways? Join the email list:https://subscribe.inpatientupdate.com/